{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T02:13:44Z","timestamp":1790648024894,"version":"4.1.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T00:00:00Z","timestamp":1691625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T00:00:00Z","timestamp":1691625600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>We assessed whether hepatic steatosis with or without significant fibrosis (determined by validated non-invasive biomarkers) is associated with an increased 10-year estimated risk for cardiovascular disease (CVD) in people with type 1 diabetes mellitus (T1DM).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We conducted a retrospective, multicenter, cross-sectional study involving 1,254 adults with established T1DM without pre-existing CVD. We used the hepatic steatosis index (HSI) and fibrosis (FIB)-4 index for non-invasively detecting hepatic steatosis (defined as HSI\u2009&gt;\u200936), with or without coexisting significant fibrosis (defined as FIB-4 index\u2009\u2265\u20091.3 or &lt;\u20091.3). We calculated the Steno type 1 risk engine and the atherosclerotic CVD (ASCVD) risk score to estimate the 10-year risk of developing a first fatal or nonfatal CVD event.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Using the Steno type 1 risk engine, a significantly greater proportion of patients with hepatic steatosis and significant fibrosis (n\u2009=\u200991) had a high 10-year estimated CVD risk compared to those with hepatic steatosis alone (n\u2009=\u2009509) or without steatosis (n\u2009=\u2009654) (75.8% vs. 23.2% vs. 24.9%, p\u2009&lt;\u20090.001). After adjustment for sex, BMI, diabetes duration, hemoglobin A1c, chronic kidney disease, and lipid-lowering medication use, patients with hepatic steatosis and significant fibrosis had an increased 10-year estimated risk of developing a first fatal or nonfatal CVD event (adjusted-odds ratio 11.4, 95% confidence interval 3.54\u201336.9) than those without steatosis. We observed almost identical results using the ASCVD risk calculator.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The 10-year estimated CVD risk is remarkably greater in T1DM adults with hepatic steatosis and significant fibrosis than in their counterparts with hepatic steatosis alone or without steatosis.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12933-023-01945-x","type":"journal-article","created":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T15:02:58Z","timestamp":1691679778000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Hepatic steatosis with significant fibrosis is associated with an increased 10-year estimated risk of cardiovascular disease in adults with type 1 diabetes mellitus"],"prefix":"10.1186","volume":"22","author":[{"given":"Alessandro","family":"Mantovani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario Luca","family":"Morieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Palmisano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Masulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efisio","family":"Cossu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco Giorgio","family":"Baroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Bonomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia Agata","family":"Cimini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gisella","family":"Cavallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Buzzetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Mignogna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frida","family":"Leonetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simonetta","family":"Bacci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Trevisan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo Maria","family":"Pollis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Aldigeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra Dei","family":"Cas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saula Vigili","family":"de Kreutzenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Targher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,10]]},"reference":[{"issue":"1","key":"1945_CR1","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41575-021-00523-4","volume":"19","author":"JV Lazarus","year":"2022","unstructured":"Lazarus JV, Mark HE, Anstee QM, Arab JP, Batterham RL, Castera L, et al. Advancing the global public health agenda for NAFLD: a consensus statement. Nat Rev Gastroenterol Hepatol. 2022;19(1):60\u201378. https:\/\/doi.org\/10.1038\/s41575-021-00523-4. Epub 2021\/10\/29.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"10319","key":"1945_CR2","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0140-6736(21)01701-3","volume":"399","author":"TH Karlsen","year":"2022","unstructured":"Karlsen TH, Sheron N, Zelber-Sagi S, Carrieri P, Dusheiko G, Bugianesi E, et al. The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. Lancet. 2022;399(10319):61\u2013116. https:\/\/doi.org\/10.1016\/S0140-6736(21)01701-3. Epub 2021\/12\/06.","journal-title":"Lancet"},{"issue":"4","key":"1945_CR3","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","volume":"77","author":"ZM Younossi","year":"2023","unstructured":"Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77(4):1335\u201347. Epub 2023\/01\/11. doi: 10.1097\/HEP.0000000000000004. PubMed PMID: 36626630; PubMed Central PMCID: PMCPMC10026948 Madrigal, Merck, Siemens, and Intercept. The remaining authors have no conflicts to report.","journal-title":"Hepatology"},{"issue":"4","key":"1945_CR4","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","volume":"71","author":"ZM Younossi","year":"2019","unstructured":"Younossi ZM, Golabi P, de Avila L, Paik JM, Srishord M, Fukui N, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol. 2019;71(4):793\u2013801. https:\/\/doi.org\/10.1016\/j.jhep.2019.06.021. Epub 2019\/07\/08.","journal-title":"J Hepatol"},{"issue":"2","key":"1945_CR5","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/nrendo.2017.173","volume":"14","author":"G Targher","year":"2018","unstructured":"Targher G, Lonardo A, Byrne CD. Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus. Nat Rev Endocrinol. 2018;14(2):99\u2013114. https:\/\/doi.org\/10.1038\/nrendo.2017.173. Epub 2017\/12\/30.","journal-title":"Nat Rev Endocrinol"},{"issue":"7","key":"1945_CR6","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/S2468-1253(21)00020-0","volume":"6","author":"G Targher","year":"2021","unstructured":"Targher G, Tilg H, Byrne CD. Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach. Lancet Gastroenterol Hepatol. 2021;6(7):578\u201388. https:\/\/doi.org\/10.1016\/S2468-1253(21)00020-0. Epub 2021\/05\/08.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"1945_CR7","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1053\/j.gastro.2022.06.073","volume":"163","author":"V Ajmera","year":"2022","unstructured":"Ajmera V, Kim BK, Yang K, Majzoub AM, Nayfeh T, Tamaki N, et al. Liver stiffness on magnetic resonance elastography and the MEFIB Index and Liver-Related outcomes in nonalcoholic fatty liver disease: a systematic review and Meta-analysis of individual participants. Gastroenterology. 2022;163(4):1079\u201389. https:\/\/doi.org\/10.1053\/j.gastro.2022.06.073. e5. Epub 2022\/07\/06.","journal-title":"Gastroenterology"},{"key":"1945_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2020.154170","author":"A Mantovani","year":"2020","unstructured":"Mantovani A, Scorletti E, Mosca A, Alisi A, Byrne CD, Targher G. Complications, morbidity and mortality of nonalcoholic fatty liver disease. Metabolism. 2020;111. https:\/\/doi.org\/10.1016\/j.metabol.2020.154170. Epub 2020\/02\/02. S:154170."},{"issue":"11","key":"1945_CR9","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/S2468-1253(21)00308-3","volume":"6","author":"A Mantovani","year":"2021","unstructured":"Mantovani A, Csermely A, Petracca G, Beatrice G, Corey KE, Simon TG, et al. Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2021;6(11):903\u201313. https:\/\/doi.org\/10.1016\/S2468-1253(21)00308-3. Epub 2021\/09\/24.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1945_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2022-327672","author":"A Mantovani","year":"2022","unstructured":"Mantovani A, Petracca G, Csermely A, Beatrice G, Bonapace S, Rossi A, et al. Non-alcoholic fatty liver disease and risk of new-onset heart failure: an updated meta-analysis of about 11 million individuals. Gut. 2022. https:\/\/doi.org\/10.1136\/gutjnl-2022-327672. PubMed PMID: 35879047. Epub 2022\/07\/26.","journal-title":"Gut"},{"issue":"1","key":"1945_CR11","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/s12933-021-01374-8","volume":"20","author":"J Park","year":"2021","unstructured":"Park J, Kim G, Kim H, Lee J, Lee YB, Jin SM, et al. The association of hepatic steatosis and fibrosis with heart failure and mortality. Cardiovasc Diabetol. 2021;20(1):197. https:\/\/doi.org\/10.1186\/s12933-021-01374-8. Epub 2021\/09\/30.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"1945_CR12","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s12933-022-01483-y","volume":"21","author":"J Park","year":"2022","unstructured":"Park J, Kim G, Kim BS, Han KD, Kwon SY, Park SH, et al. The associations of hepatic steatosis and fibrosis using fatty liver index and BARD score with cardiovascular outcomes and mortality in patients with new-onset type 2 diabetes: a nationwide cohort study. Cardiovasc Diabetol. 2022;21(1):53. https:\/\/doi.org\/10.1186\/s12933-022-01483-y. Epub 2022\/04\/18.","journal-title":"Cardiovasc Diabetol"},{"key":"1945_CR13","doi-asserted-by":"publisher","first-page":"110191","DOI":"10.1016\/j.diabres.2022.110191","volume":"194","author":"J Park","year":"2022","unstructured":"Park J, Kim G, Kim BS, Han KD, Yoon Kwon S, Hee Park S, et al. The association between changes in hepatic steatosis and hepatic fibrosis with cardiovascular outcomes and mortality in patients with New-Onset type 2 diabetes: a nationwide cohort study. Diabetes Res Clin Pract. 2022;194:110191. https:\/\/doi.org\/10.1016\/j.diabres.2022.110191. Epub 2022\/12\/07.","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"1945_CR14","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1186\/s12933-022-01725-z","volume":"21","author":"J Park","year":"2022","unstructured":"Park J, Kim G, Kim H, Lee J, Jin SM, Kim JH. The associations between changes in hepatic steatosis and heart failure and mortality: a nationwide cohort study. Cardiovasc Diabetol. 2022;21(1):287. https:\/\/doi.org\/10.1186\/s12933-022-01725-z. Epub 2022\/12\/24.","journal-title":"Cardiovasc Diabetol"},{"issue":"6","key":"1945_CR15","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1136\/gutjnl-2017-313884","volume":"66","author":"LA Adams","year":"2017","unstructured":"Adams LA, Anstee QM, Tilg H, Targher G. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut. 2017;66(6):1138\u201353. https:\/\/doi.org\/10.1136\/gutjnl-2017-313884. Epub 2017\/03\/21.","journal-title":"Gut"},{"issue":"11","key":"1945_CR16","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1002\/hep4.1419","volume":"3","author":"JM Paik","year":"2019","unstructured":"Paik JM, Henry L, De Avila L, Younossi E, Racila A, Younossi ZM. Mortality related to nonalcoholic fatty liver disease is increasing in the United States. Hepatol Commun. 2019;3(11):1459\u201371. https:\/\/doi.org\/10.1002\/hep4.1419. Epub 2019\/11\/09.","journal-title":"Hepatol Commun"},{"issue":"10","key":"1945_CR17","doi-asserted-by":"publisher","first-page":"e1001321","DOI":"10.1371\/journal.pmed.1001321","volume":"9","author":"SJ Livingstone","year":"2012","unstructured":"Livingstone SJ, Looker HC, Hothersall EJ, Wild SH, Lindsay RS, Chalmers J, et al. Risk of cardiovascular disease and total mortality in adults with type 1 diabetes: scottish registry linkage study. PLoS Med. 2012;9(10):e1001321. https:\/\/doi.org\/10.1371\/journal.pmed.1001321. Epub 2012\/10\/12.","journal-title":"PLoS Med"},{"issue":"10146","key":"1945_CR18","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/S0140-6736(18)31506-X","volume":"392","author":"A Rawshani","year":"2018","unstructured":"Rawshani A, Sattar N, Franzen S, Rawshani A, Hattersley AT, Svensson AM, et al. Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study. Lancet. 2018;392(10146):477\u201386. https:\/\/doi.org\/10.1016\/S0140-6736(18)31506-X. PubMed PMID: 30129464; PubMed Central PMCID: PMCPMC6828554. Epub 2018\/08\/22.","journal-title":"Lancet"},{"issue":"1","key":"1945_CR19","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1001\/jama.2014.16425","volume":"313","author":"SJ Livingstone","year":"2015","unstructured":"Livingstone SJ, Levin D, Looker HC, Lindsay RS, Wild SH, Joss N, et al. Estimated life expectancy in a scottish cohort with type 1 diabetes, 2008\u20132010. JAMA. 2015;313(1):37\u201344. https:\/\/doi.org\/10.1001\/jama.2014.16425. Epub 2015\/01\/07.","journal-title":"JAMA"},{"key":"1945_CR20","doi-asserted-by":"publisher","first-page":"26805","DOI":"10.1038\/srep26805","volume":"6","author":"L Zhang","year":"2016","unstructured":"Zhang L, Guo K, Lu J, Zhao F, Yu H, Han J, et al. Nonalcoholic fatty liver disease is Associated with increased carotid intima-media thickness in type 1 Diabetic patients. Sci Rep. 2016;6:26805. https:\/\/doi.org\/10.1038\/srep26805. Epub 2016\/05\/27.","journal-title":"Sci Rep"},{"issue":"4","key":"1945_CR21","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.jhep.2010.04.030","volume":"53","author":"G Targher","year":"2010","unstructured":"Targher G, Bertolini L, Padovani R, Rodella S, Zoppini G, Pichiri I, et al. Prevalence of non-alcoholic fatty liver disease and its association with cardiovascular disease in patients with type 1 diabetes. J Hepatol. 2010;53(4):713\u20138. PubMed PMID: 20619918.","journal-title":"J Hepatol"},{"issue":"5","key":"1945_CR22","first-page":"535","volume":"35","author":"G Targher","year":"2012","unstructured":"Targher G, Pichiri I, Zoppini G, Trombetta M, Bonora E. Increased prevalence of cardiovascular disease in type 1 diabetic patients with non-alcoholic fatty liver disease. J Endocrinol Invest. 2012;35(5):535\u201340. Epub 2011\/07\/29. doi: 10.3275\/7875. PubMed PMID: 21795844.","journal-title":"J Endocrinol Invest"},{"key":"1945_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2016.10.040","author":"A Mantovani","year":"2016","unstructured":"Mantovani A, Mingolla L, Rigolon R, Pichiri I, Cavalieri V, Zoppini G, et al. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular disease in adult patients with type 1 diabetes. Int J Cardiol. 2016;225. https:\/\/doi.org\/10.1016\/j.ijcard.2016.10.040. Epub 2016\/10\/22. :387 \u2013 91."},{"issue":"11","key":"1945_CR24","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1161\/CIRCULATIONAHA.115.018844","volume":"133","author":"D Vistisen","year":"2016","unstructured":"Vistisen D, Andersen GS, Hansen CS, Hulman A, Henriksen JE, Bech-Nielsen H, et al. Prediction of First Cardiovascular Disease Event in Type 1 diabetes Mellitus: the Steno type 1 risk engine. Circulation. 2016;133(11):1058\u201366. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.115.018844. Epub 2016\/02\/19.","journal-title":"Circulation"},{"issue":"25 Suppl 2","key":"1945_CR25","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1161\/01.cir.0000437741.48606.98","volume":"129","author":"DC Goff Jr","year":"2014","unstructured":"Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, D\u2019Agostino RB, Gibbons R, et al. 2013 ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 Suppl 2):49\u201373. https:\/\/doi.org\/10.1161\/01.cir.0000437741.48606.98. Epub 2013\/11\/14.","journal-title":"Circulation"},{"key":"1945_CR26","doi-asserted-by":"publisher","unstructured":"Dei Cas A, Aldigeri R, Mantovani A, Masulli M, Palmisano L, Cavalot F et al. Sex differences in cardiovascular disease and cardiovascular risk estimation in patients with type 1 diabetes. J Clin Endocrinol Metab. 2023. Epub 2023\/03\/08. doi: https:\/\/doi.org\/10.1210\/clinem\/dgad127. PubMed PMID: 36881927.","DOI":"10.1210\/clinem\/dgad127"},{"issue":"Suppl 1","key":"1945_CR27","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2337\/dc23-S002","volume":"46","author":"NA ElSayed","year":"2023","unstructured":"ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. 2. Classification and diagnosis of diabetes: Standards of Care in Diabetes-2023. Diabetes Care. 2023;46(Suppl 1):19\u2013S40. https:\/\/doi.org\/10.2337\/dc23-S002. Epub 2022\/12\/13.","journal-title":"Diabetes Care"},{"key":"1945_CR28","doi-asserted-by":"publisher","unstructured":"Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604\u201312. https:\/\/doi.org\/10.7326\/0003-4819-150-9-200905050-00006. Epub 2009\/05\/06.","DOI":"10.7326\/0003-4819-150-9-200905050-00006"},{"issue":"7","key":"1945_CR29","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.dld.2009.08.002","volume":"42","author":"JH Lee","year":"2010","unstructured":"Lee JH, Kim D, Kim HJ, Lee CH, Yang JI, Kim W, et al. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis. 2010;42(7):503\u20138. PubMed PMID: 19766548.","journal-title":"Dig Liver Dis"},{"key":"1945_CR30","doi-asserted-by":"publisher","unstructured":"Morieri ML, Vitturi N, Avogaro A, Targher G, Fadini GP, Society D-TDNotID. Prevalence of hepatic steatosis in patients with type 2 diabetes and response to glucose-lowering treatments. A multicenter retrospective study in Italian specialist care. J Endocrinol Invest. 2021;44(9):1879-89. Epub 2021\/01\/13. doi: https:\/\/doi.org\/10.1007\/s40618-021-01501-y. PubMed PMID: 33432553.","DOI":"10.1007\/s40618-021-01501-y"},{"issue":"1","key":"1945_CR31","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1111\/jgh.13814","volume":"33","author":"L Sviklane","year":"2018","unstructured":"Sviklane L, Olmane E, Dzerve Z, Kupcs K, Pirags V, Sokolovska J. Fatty liver index and hepatic steatosis index for prediction of non-alcoholic fatty liver disease in type 1 diabetes. J Gastroenterol Hepatol. 2018;33(1):270\u20136. https:\/\/doi.org\/10.1111\/jgh.13814. Epub 2017\/05\/04.","journal-title":"J Gastroenterol Hepatol"},{"key":"1945_CR32","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.12.036","author":"L Castera","year":"2019","unstructured":"Castera L, Friedrich-Rust M, Loomba R. Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2019;156(5):1264. https:\/\/doi.org\/10.1053\/j.gastro.2018.12.036. Epub 2019\/01\/21. 81 e4."},{"issue":"1","key":"1945_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.numecd.2021.04.028","volume":"32","author":"A Associazione Italiana per lo Studio","year":"2021","unstructured":"Associazione Italiana per lo Studio del Fegato SIdD A, Italiana S, dO, Members of the guidelines p, Coordinator, Members A, Members SID. Non-alcoholic fatty liver disease in adults 2021: a clinical practice guideline of the Italian Association for the study of the liver (AISF), the italian society of Diabetology (SID) and the italian society of obesity (SIO). Nutr Metab Cardiovasc Dis. 2021;32(1):1\u201316. https:\/\/doi.org\/10.1016\/j.numecd.2021.04.028. Epub 2021\/12\/21. PubMed PMID: 34924246.","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"5","key":"1945_CR34","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","volume":"77","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797\u2013835. https:\/\/doi.org\/10.1097\/HEP.0000000000000323. Epub 2023\/02\/03.","journal-title":"Hepatology"},{"issue":"1","key":"1945_CR35","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111\u201388. https:\/\/doi.org\/10.1093\/eurheartj\/ehz455. Epub 2019\/09\/11.","journal-title":"Eur Heart J"},{"key":"1945_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.11.003","author":"SM Grundy","year":"2019","unstructured":"Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol. A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73(24):e285\u2013e350. https:\/\/doi.org\/10.1016\/j.jacc.2018.11.003. PubMed PMID: 30423393. 2018 Epub 2018\/11\/14."},{"issue":"9","key":"1945_CR37","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1136\/gutjnl-2020-320622","volume":"69","author":"G Targher","year":"2020","unstructured":"Targher G, Byrne CD, Tilg H. NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. Gut. 2020;69(9):1691\u2013705. https:\/\/doi.org\/10.1136\/gutjnl-2020-320622. Epub 2020\/04\/24.","journal-title":"Gut"},{"issue":"2","key":"1945_CR38","doi-asserted-by":"publisher","first-page":"101215","DOI":"10.1016\/j.diabet.2020.101215","volume":"47","author":"G Targher","year":"2021","unstructured":"Targher G, Corey KE, Byrne CD. NAFLD, and cardiovascular and cardiac diseases: factors influencing risk, prediction and treatment. Diabetes Metab. 2021;47(2):101215. https:\/\/doi.org\/10.1016\/j.diabet.2020.101215. Epub 2020\/12\/10.","journal-title":"Diabetes Metab"},{"issue":"7","key":"1945_CR39","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/s41575-018-0010-0","volume":"15","author":"QM Anstee","year":"2018","unstructured":"Anstee QM, Mantovani A, Tilg H, Targher G. Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2018;15(7):425\u201339. https:\/\/doi.org\/10.1038\/s41575-018-0010-0. Epub 2018\/05\/02.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"6","key":"1945_CR40","doi-asserted-by":"publisher","first-page":"e168","DOI":"10.1161\/ATV.0000000000000153","volume":"42","author":"PB Duell","year":"2022","unstructured":"Duell PB, Welty FK, Miller M, Chait A, Hammond G, Ahmad Z, et al. Nonalcoholic fatty liver Disease and Cardiovascular Risk: A Scientific Statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2022;42(6):e168\u2013e85. 10.1161. Epub 2022\/04\/15.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1945_CR41","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k2734","author":"CD Byrne","year":"2018","unstructured":"Byrne CD, Patel J, Scorletti E, Targher G. Tests for diagnosing and monitoring non-alcoholic fatty liver disease in adults. BMJ. 2018;362. https:\/\/doi.org\/10.1136\/bmj.k2734. Epub 2018\/07\/14. :k2734."}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-023-01945-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-023-01945-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-023-01945-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T13:16:45Z","timestamp":1700399805000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-023-01945-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,10]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1945"],"URL":"https:\/\/doi.org\/10.1186\/s12933-023-01945-x","relation":{"references":[{"id-type":"uri","id":"","asserted-by":"subject"},{"id-type":"uri","id":"","asserted-by":"subject"},{"id-type":"uri","id":"","asserted-by":"subject"},{"id-type":"uri","id":"","asserted-by":"subject"},{"id-type":"uri","id":"","asserted-by":"subject"}]},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,10]]},"assertion":[{"value":"26 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study protocol was approved by the \u201cComitato etico per la Sperimentazione Clinica della Provincia di Padova\u201d (code #63553, October 18th, 2018) and by the ethics committee of each participating center. Written informed consent was collected accordingly to the requests of each local ethics committee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"We agree to the publication of the data; we also declare that the data are original and are not under review elsewhere.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"204"}}